Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Hypoglycemia - Overview Hypoglycemia - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Hypoglycemia - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Hypoglycemia - Companies Involved in Therapeutics Development Adocia SAS AMAG Pharmaceuticals Inc Arecor Ltd Eiger BioPharmaceuticals Inc Eli Lilly and Co LATITUDE Pharmaceuticals Inc Novartis AG Rezolute Inc Sosei Heptares Therakind Ltd USV Pvt Ltd XERIS Pharmaceuticals Inc Zealand Pharma AS Zucara Therapeutics Inc Hypoglycemia - Drug Profiles avexitide acetate - Drug Profile Product Description Mechanism Of Action R&D Progress dasiglucagon - Drug Profile Product Description Mechanism Of Action R&D Progress Drug for Hypoglycemia - Drug Profile Product Description Mechanism Of Action R&D Progress glucagon - Drug Profile Product Description Mechanism Of Action R&D Progress glucagon - Drug Profile Product Description Mechanism Of Action R&D Progress glucagon - Drug Profile Product Description Mechanism Of Action R&D Progress glucagon - Drug Profile Product Description Mechanism Of Action R&D Progress glucagon - Drug Profile Product Description Mechanism Of Action R&D Progress glucagon biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress LY-3143753 - Drug Profile Product Description Mechanism Of Action R&D Progress LY-3185643 - Drug Profile Product Description Mechanism Of Action R&D Progress LY-900018 - Drug Profile Product Description Mechanism Of Action R&D Progress pasireotide - Drug Profile Product Description Mechanism Of Action R&D Progress RZ-358 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Antagonize GLP-1 Receptor for Congenital Hyperinsulinism and Hypoglycemia - Drug Profile Product Description Mechanism Of Action R&D Progress ZT-01 - Drug Profile Product Description Mechanism Of Action R&D Progress Hypoglycemia - Dormant Projects Hypoglycemia - Discontinued Products Hypoglycemia - Product Development Milestones Featured News & Press Releases Mar 25, 2019: Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019 Mar 25, 2019: Xeris Pharmaceuticals presents new clinical and economic impact data on its developmental ready-to-use Glucagon Mar 14, 2019: Xeris Pharmaceuticals doses first patient in phase 2 trial evaluating its ready-to-use glucagon to address exercise-induced hypoglycemia Mar 07, 2019: Zealand Pharma begins dosing in Phase III trial for CHI Feb 13, 2019: XOMA receives $5.5 Million payment from Rezolute Feb 12, 2019: Adocia to present new clinical data on BioChaperone Glucagon at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019) Feb 04, 2019: Eiger BioPharmaceuticals announces oral presentation of phase 2 PREVENT study of avexitide in post-bariatric hypoglycemia (PBH) at upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans Jan 17, 2019: LATITUDE Pharmaceuticals receives notice of allowance for U.S. Patent Covering Stabilized Aqueous Glucagon Formulations Dec 20, 2018: European medicines agency grants orphan drug designation for Xeris’ investigational ready to use glucagon for the treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS) Dec 11, 2018: Eiger BioPharmaceuticals provides update on Avexitide at 2018 R&D Day Nov 12, 2018: Xeris Pharmaceuticals releases additional phase 3 clinical trial data on its ready-to-use Liquid Glucagon Pen Oct 23, 2018: Xeris Pharmaceuticals announces FDA acceptance for review of NDA for its ready-to-use Glucagon Rescue Pen Oct 16, 2018: Eiger BioPharmaceuticals announces positive results in phase 2 PREVENT study of Avexitide targeting GLP-1 in post-bariatric hypoglycemia (PBH) Sep 27, 2018: Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children Sep 18, 2018: Zealand Pharma achieves primary and key secondary endpoints in pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Hypoglycemia, H1 2019 Number of Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 Number of Products by Stage and Target, H1 2019 Number of Products by Stage and Mechanism of Action, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Hypoglycemia - Pipeline by Adocia SAS, H1 2019 Hypoglycemia - Pipeline by AMAG Pharmaceuticals Inc, H1 2019 Hypoglycemia - Pipeline by Arecor Ltd, H1 2019 Hypoglycemia - Pipeline by Eiger BioPharmaceuticals Inc, H1 2019 Hypoglycemia - Pipeline by Eli Lilly and Co, H1 2019 Hypoglycemia - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2019 Hypoglycemia - Pipeline by Novartis AG, H1 2019 Hypoglycemia - Pipeline by Rezolute Inc, H1 2019 Hypoglycemia - Pipeline by Sosei Heptares, H1 2019 Hypoglycemia - Pipeline by Therakind Ltd, H1 2019 Hypoglycemia - Pipeline by USV Pvt Ltd, H1 2019 Hypoglycemia - Pipeline by XERIS Pharmaceuticals Inc, H1 2019 Hypoglycemia - Pipeline by Zealand Pharma AS, H1 2019 Hypoglycemia - Pipeline by Zucara Therapeutics Inc, H1 2019 Hypoglycemia - Dormant Projects, H1 2019 Hypoglycemia - Discontinued Products, H1 2019List of Figures Number of Products under Development for Hypoglycemia, H1 2019 Number of Products under Development by Companies, H1 2019 Number of Products by Targets, H1 2019 Number of Products by Stage and Targets, H1 2019 Number of Products by Mechanism of Actions, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Routes of Administration, H1 2019 Number of Products by Stage and Routes of Administration, H1 2019 Number of Products by Molecule Types, H1 2019 Number of Products by Stage and Molecule Types, H1 2019

Adocia SAS AMAG Pharmaceuticals Inc Arecor Ltd Eiger BioPharmaceuticals Inc Eli Lilly and Co LATITUDE Pharmaceuticals Inc Novartis AG Rezolute Inc Sosei Heptares Therakind Ltd USV Pvt Ltd XERIS Pharmaceuticals Inc Zealand Pharma AS Zucara Therapeutics Inc